Apellis Pharmaceuticals, Inc. — Director's Dealing 2018

Feb 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2018-02-16

Reporting Person: Sullivan Timothy Eugene (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-16	Stock Option (right to buy)	$14.95	A	25000	Acquired	2028-02-15	Common Stock (25000)	Direct

Footnotes

F1: This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.